Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Abstract Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients. Additionall...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kazushi Uneda, Yuki Kawai, Takayuki Yamada, Sho Kinguchi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bdeeefe0317c4f1680ebe0f2d15b978a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bdeeefe0317c4f1680ebe0f2d15b978a
record_format	dspace
spelling	oai:doaj.org-article:bdeeefe0317c4f1680ebe0f2d15b978a2021-12-02T15:43:08ZSystematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients10.1038/s41598-021-89620-72045-2322https://doaj.org/article/bdeeefe0317c4f1680ebe0f2d15b978a2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89620-7https://doaj.org/toc/2045-2322Abstract Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients. Additionally, the two drugs reduce body mass. However, it is unknown which drug is more effective at reducing the risk of CVD in such patients. We searched Medline, EMBASE, and Cochrane Library records to February 20, 2021 and performed a network meta-analysis to compare the efficacy with which the drugs reduced the risk of major adverse cardiovascular events (MACE). We included 102,728 patients in 12 studies containing data of obesity subgroup analyses. In T2DM patients with obesity, GLP-1 RAs significantly reduced the risk of MACE versus placebo (relative risk, RR [95% confidence interval, CI]: 0.88 [0.81–0.96]), whereas SGLT-2 inhibitors showed a tendency (RR [95% CI]: 0.91 [0.83–1.00]). In an indirect comparison, GLP-1 RAs were not associated with a significant difference in MACE compared with SGLT-2 inhibitors (RR [95% CI]: 0.97 [0.85–1.09]). Thus, GLP-1 RAs are effective at preventing MACE than placebo in T2DM patients with obesity, although further studies are warranted to conclude their superiority to SGLT-2 inhibitors.Kazushi UnedaYuki KawaiTakayuki YamadaSho KinguchiKengo AzushimaTomohiko KanaokaYoshiyuki ToyaHiromichi WakuiKouichi TamuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kazushi Uneda Yuki Kawai Takayuki Yamada Sho Kinguchi Kengo Azushima Tomohiko Kanaoka Yoshiyuki Toya Hiromichi Wakui Kouichi Tamura Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
description	Abstract Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients. Additionally, the two drugs reduce body mass. However, it is unknown which drug is more effective at reducing the risk of CVD in such patients. We searched Medline, EMBASE, and Cochrane Library records to February 20, 2021 and performed a network meta-analysis to compare the efficacy with which the drugs reduced the risk of major adverse cardiovascular events (MACE). We included 102,728 patients in 12 studies containing data of obesity subgroup analyses. In T2DM patients with obesity, GLP-1 RAs significantly reduced the risk of MACE versus placebo (relative risk, RR [95% confidence interval, CI]: 0.88 [0.81–0.96]), whereas SGLT-2 inhibitors showed a tendency (RR [95% CI]: 0.91 [0.83–1.00]). In an indirect comparison, GLP-1 RAs were not associated with a significant difference in MACE compared with SGLT-2 inhibitors (RR [95% CI]: 0.97 [0.85–1.09]). Thus, GLP-1 RAs are effective at preventing MACE than placebo in T2DM patients with obesity, although further studies are warranted to conclude their superiority to SGLT-2 inhibitors.
format	article
author	Kazushi Uneda Yuki Kawai Takayuki Yamada Sho Kinguchi Kengo Azushima Tomohiko Kanaoka Yoshiyuki Toya Hiromichi Wakui Kouichi Tamura
author_facet	Kazushi Uneda Yuki Kawai Takayuki Yamada Sho Kinguchi Kengo Azushima Tomohiko Kanaoka Yoshiyuki Toya Hiromichi Wakui Kouichi Tamura
author_sort	Kazushi Uneda
title	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
title_short	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
title_full	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
title_fullStr	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
title_full_unstemmed	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
title_sort	systematic review and meta-analysis for prevention of cardiovascular complications using glp-1 receptor agonists and sglt-2 inhibitors in obese diabetic patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bdeeefe0317c4f1680ebe0f2d15b978a
work_keys_str_mv	AT kazushiuneda systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT yukikawai systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT takayukiyamada systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT shokinguchi systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT kengoazushima systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT tomohikokanaoka systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT yoshiyukitoya systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT hiromichiwakui systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients AT kouichitamura systematicreviewandmetaanalysisforpreventionofcardiovascularcomplicationsusingglp1receptoragonistsandsglt2inhibitorsinobesediabeticpatients
_version_	1718385832828600320

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Ejemplares similares